MTD vs ILMN vs DGX
161 measures in 16 categories, one definition each, computed from filings and market data.
MTD62.7
Mettler-Toledo International Inc.
Healthcare · Medical - Diagnostics & Research
$1,622.29 −1.12%$32.5B mkt cap
Score DNA
ILMN57.6
Illumina, Inc.
Healthcare · Medical - Diagnostics & Research
$262.54 −2.01%$39.6B mkt cap
Score DNA
DGX62.3
Quest Diagnostics Incorporated
Healthcare · Medical - Diagnostics & Research
$235.00 −1.74%$25.9B mkt cap
Score DNA
Price, rebased to 100 three years ago
MTD ILMN DGX · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | MTD | ILMN | DGX |
|---|---|---|---|
| Insider open-market buys, 180d | 0 | 0 | 0 |
| Insider $ bought, 180d | — | — | — |
| Congress purchases, 180d | 1 | 0 | 4 |
| Last Congress purchase | 2026-09-11 | — | 2026-09-04 |
| 13F net change in holders | −15 | +92 | +42 |
| ETFs adding shares, 30d | 946 | 1,058 | 1,044 |
| ETFs trimming, 30d | 955 | 840 | 983 |
| Net ETF funds, 30d | −9 | +218 | +61 |
Valuation
16 measures| Measure | MTD | ILMN | DGX |
|---|---|---|---|
| P/E (TTM) | 35.9x
53rd
|
48.1x
82nd
|
24.4x
6th
|
| PEG (P/E ÷ 3-yr EPS CAGR) | 9.66
100th
|
— | 2.24
12th
|
| Price / sales | 7.9x
72nd
|
8.8x
76th
|
2.2x
17th
|
| Price / book | — | 14.0x
89th
|
3.5x
48th
|
| Price / tangible book | — | 23.6x
71st
|
— |
| Price / free cash flow | 37.6x
63rd
|
42.2x
79th
|
21.3x
21st
|
| Price / operating cash flow | 33.3x
70th
|
36.2x
78th
|
14.6x
9th
|
| Enterprise value | $34.6B
72nd
|
$41.0B
76th
|
$31.7B
66th
|
| EV / sales | 8.4x
72nd
|
9.1x
76th
|
2.7x
21st
|
| EV / EBITDA | 26.5x
62nd
|
29.5x
76th
|
15.0x
14th
|
| EV / EBIT | 29.5x
53rd
|
36.8x
76th
|
19.3x
6th
|
| EV / free cash flow | 40.0x
63rd
|
43.7x
74th
|
26.0x
26th
|
| Earnings yield | 2.8%
69th
|
2.1%
52nd
|
4.1%
97th
|
| FCF yield | 2.7%
59th
|
2.4%
48th
|
4.7%
86th
|
| Operating cash flow yield | 3.0%
45th
|
2.8%
38th
|
6.8%
93rd
|
| Graham number (per share) | $25.35
24th
|
$47.44
35th
|
$119.65
88th
|
Profitability (TTM)
12 measures| Measure | MTD | ILMN | DGX |
|---|---|---|---|
| Gross margin | 58.4%
59th
|
66.8%
79th
|
33.1%
31st
|
| EBITDA margin | 31.5%
90th
|
30.9%
86th
|
18.3%
55th
|
| Operating margin | 28.4%
93rd
|
21.0%
79th
|
14.1%
66th
|
| EBIT margin | 28.4%
93rd
|
24.8%
90th
|
14.2%
66th
|
| Net margin | 21.9%
93rd
|
18.4%
79th
|
9.2%
59th
|
| NOPAT margin | 23.4%
97th
|
17.0%
72nd
|
11.0%
59th
|
| FCF margin | 20.9%
83rd
|
20.9%
79th
|
10.6%
55th
|
| Operating cash flow margin | 23.6%
76th
|
24.4%
83rd
|
15.3%
52nd
|
| R&D / revenue | 5.0%
34th
|
21.3%
86th
|
0.0%
0th
|
| SG&A / revenue | 24.9%
38th
|
24.1%
31st
|
17.5%
21st
|
| Stock comp / revenue | 0.6%
7th
|
1.6%
29th
|
0.5%
4th
|
| Effective tax rate | 17.5%
31st
|
18.7%
41st
|
22.6%
93rd
|
Returns on capital
11 measures| Measure | MTD | ILMN | DGX |
|---|---|---|---|
| ROE (on average equity) | — | 32.4%
93rd
|
14.4%
74th
|
| ROA | 25.6%
93rd
|
13.0%
86th
|
6.5%
69th
|
| ROIC | 46.7%
97th
|
18.2%
86th
|
9.5%
66th
|
| ROCE | 47.5%
93rd
|
22.0%
90th
|
10.9%
76th
|
| Return on tangible assets | 33.2%
97th
|
17.5%
90th
|
10.0%
79th
|
| Cash ROIC (OCF / invested capital) | 47.0%
90th
|
26.1%
83rd
|
13.4%
55th
|
| Gross profitability (GP / assets) | 65.7%
90th
|
45.1%
76th
|
22.6%
52nd
|
| ROIC, 3-yr average | 42.7%
100th
|
-15.2%
17th
|
7.1%
75th
|
| ROIC, 5-yr average | — | -22.8%
17th
|
9.3%
79th
|
| ROE, 5-yr average | — | -38.2%
16th
|
15.1%
80th
|
| Incremental ROIC | 142.4%
85th
|
-50.5%
26th
|
184.9%
89th
|
Growth
17 measures| Measure | MTD | ILMN | DGX |
|---|---|---|---|
| Revenue growth (TTM YoY) | 6.9%
43rd
|
4.9%
29th
|
9.9%
61st
|
| Revenue growth (QoQ) | 8.5%
59th
|
6.2%
38th
|
5.1%
24th
|
| Revenue CAGR, 3 yr | 1.5%
26th
|
0.2%
15th
|
6.8%
56th
|
| Revenue CAGR, 5 yr | 3.5%
33rd
|
2.5%
30th
|
0.9%
26th
|
| Gross profit CAGR, 3 yr | 1.9%
30th
|
2.6%
33rd
|
6.3%
59th
|
| Operating income CAGR, 3 yr | 0.1%
33rd
|
— | 11.5%
67th
|
| Net income growth (TTM YoY) | 9.1%
31st
|
-34.4%
12th
|
11.8%
50th
|
| Net income CAGR, 3 yr | 0.6%
33rd
|
— | 10.3%
83rd
|
| EPS growth (TTM YoY) | 12.5%
31st
|
-32.3%
12th
|
12.8%
38th
|
| EPS CAGR, 3 yr | 3.7%
33rd
|
— | 10.9%
75th
|
| EPS CAGR, 5 yr | 8.2%
64th
|
0.6%
57th
|
-11.7%
21st
|
| FCF growth (TTM YoY) | 1.9%
44th
|
-8.9%
22nd
|
-0.3%
33rd
|
| FCF CAGR, 3 yr | 0.2%
7th
|
— | 11.6%
64th
|
| Operating cash flow CAGR, 3 yr | 0.2%
24th
|
73.4%
88th
|
8.9%
59th
|
| Book value CAGR, 3 yr | — | -23.5%
4th
|
7.0%
72nd
|
| Dividend CAGR, 3 yr | — | — | 2.6%
60th
|
| Sustainable growth rate | — | 32.4%
88th
|
9.5%
44th
|
Margin history & stability
7 measures| Measure | MTD | ILMN | DGX |
|---|---|---|---|
| Gross margin, 3-yr average | 57.9%
64th
|
65.1%
82nd
|
33.0%
29th
|
| Operating margin, 3-yr average | 28.3%
93rd
|
-2.8%
39th
|
13.9%
68th
|
| Net margin, 3-yr average | 21.4%
96th
|
-7.0%
32nd
|
9.1%
71st
|
| FCF margin, 3-yr average | 22.3%
93rd
|
17.7%
75th
|
10.5%
50th
|
| Revenue stability (0-1) | 0.71
39th
|
0.55
21st
|
0.03
0th
|
| Earnings stability (0-1) | 0.46
50th
|
0.01
4th
|
0.51
61st
|
| Margin stability (0-1) | 0.99
100th
|
0.95
57th
|
0.90
46th
|
Liquidity (latest quarter)
7 measures| Measure | MTD | ILMN | DGX |
|---|---|---|---|
| Cash & short-term investments | $51.4M
0th
|
$1.2B
86th
|
$626.0M
59th
|
| Net cash (− = net debt) | −$2.1B
34th
|
−$1.4B
45th
|
−$5.8B
14th
|
| Working capital | $146.9M
10th
|
$1.3B
83rd
|
$1.1B
72nd
|
| Current ratio | 1.12
10th
|
1.80
38th
|
1.59
28th
|
| Quick ratio | 0.78
7th
|
1.40
31st
|
1.46
34th
|
| Cash ratio (cash + ST investments / current liabilities) | 0.04
0th
|
0.74
38th
|
0.35
28th
|
| Defensive interval (days) | 231 days
7th
|
342 days
24th
|
381 days
34th
|
Leverage & solvency (latest quarter)
13 measures| Measure | MTD | ILMN | DGX |
|---|---|---|---|
| Total debt | $2.1B
55th
|
$2.5B
66th
|
$6.4B
86th
|
| Debt / equity | — | 0.89
85th
|
0.85
81st
|
| Net debt / equity | — | 0.48
70th
|
0.77
81st
|
| Debt / assets | 57.5%
93rd
|
38.0%
79th
|
37.7%
76th
|
| Debt / capital | 99.4%
100th
|
47.1%
82nd
|
45.9%
79th
|
| Debt / EBITDA | 1.62
19th
|
1.82
24th
|
3.02
43rd
|
| Net debt / EBITDA | 1.58
38th
|
0.98
24th
|
2.72
52nd
|
| Interest coverage (EBIT / interest) | 16.9x
88th
|
11.2x
76th
|
6.3x
68th
|
| Cash interest coverage | 14.1x
72nd
|
10.9x
68th
|
6.8x
52nd
|
| Debt payback (years of OCF) | 2.2 yrs
30th
|
2.3 yrs
35th
|
3.6 yrs
48th
|
| Liabilities / assets | 99.7%
97th
|
57.3%
76th
|
53.8%
72nd
|
| IS credit model rating | AA | AA | A |
| Implied credit spread (bps) | 80
14th
|
80
14th
|
150
34th
|
Efficiency
11 measures| Measure | MTD | ILMN | DGX |
|---|---|---|---|
| Asset turnover | 1.17
86th
|
0.71
69th
|
0.70
66th
|
| Fixed asset turnover | 4.97
66th
|
4.06
45th
|
3.99
41st
|
| Inventory turnover | 4.3
28th
|
2.5
4th
|
36.8
100th
|
| Receivables turnover | 5.9
34th
|
6.1
38th
|
7.5
79th
|
| Days sales outstanding | 62 days
66th
|
60 days
62nd
|
49 days
21st
|
| Days inventory outstanding | 85 days
72nd
|
147 days
96th
|
10 days
0th
|
| Days payables outstanding | 47 days
55th
|
53 days
66th
|
31 days
38th
|
| Cash conversion cycle (days) | 100 days
69th
|
155 days
93rd
|
28 days
7th
|
| Capex / revenue | 2.7%
34th
|
3.5%
52nd
|
4.8%
69th
|
| Capex / depreciation | 0.85
69th
|
0.57
34th
|
1.18
83rd
|
| Operating expense ratio | 30.8%
34th
|
45.3%
52nd
|
18.7%
14th
|
Cash flow & earnings quality
7 measures| Measure | MTD | ILMN | DGX |
|---|---|---|---|
| Operating cash flow / net income | 1.08
6th
|
1.33
35th
|
1.67
71st
|
| FCF / net income | 0.95
18th
|
1.14
47th
|
1.15
53rd
|
| FCF / operating cash flow | 88.6%
70th
|
85.8%
65th
|
68.8%
35th
|
| Capex / operating cash flow | 11.4%
30th
|
14.2%
35th
|
31.2%
65th
|
| Accruals ratio | -2.0%
79th
|
-4.2%
52nd
|
-4.3%
48th
|
| Sloan accruals ratio | -3.4%
31st
|
-3.1%
34th
|
2.5%
69th
|
| Earnings quality score (0-1) | 1.00
24th
|
1.00
24th
|
1.00
24th
|
Scores & forensic checks
15 measures| Measure | MTD | ILMN | DGX |
|---|---|---|---|
| IS score | 63
72nd
|
58
59th
|
62
69th
|
| IS profitability | 75
90th
|
80
93rd
|
46
62nd
|
| IS growth | 62
64th
|
28
7th
|
55
50th
|
| IS value | 35
38th
|
29
7th
|
53
86th
|
| IS momentum | 74
54th
|
58
25th
|
83
75th
|
| IS risk (safety) | 100
62nd
|
100
62nd
|
80
38th
|
| IS quality | 62
48th
|
83
83rd
|
75
76th
|
| IS balance sheet | 42
38th
|
76
83rd
|
51
52nd
|
| IS earnings quality | 74
69th
|
75
79th
|
77
93rd
|
| IS cash flow | 63
62nd
|
64
66th
|
55
55th
|
| Piotroski F-score (0-9) | 8
76th
|
7
59th
|
8
76th
|
| Altman Z-score | 10.1
86th
|
5.7
72nd
|
3.5
55th
|
| Beneish M-score | −2.51
82nd
|
−2.56
64th
|
−2.51
79th
|
| Ohlson O-score | −5.36
93rd
|
−8.01
52nd
|
−8.23
48th
|
| IS credit score | 86
79th
|
87
83rd
|
70
59th
|
Size (TTM)
8 measures| Measure | MTD | ILMN | DGX |
|---|---|---|---|
| Market cap | $32.5B
72nd
|
$39.6B
76th
|
$25.9B
69th
|
| Revenue | $4.1B
66th
|
$4.5B
69th
|
$11.6B
86th
|
| EBITDA | $1.3B
72nd
|
$1.4B
76th
|
$2.1B
86th
|
| Net income | $905.6M
76th
|
$825.0M
72nd
|
$1.1B
83rd
|
| Free cash flow | $864.0M
69th
|
$939.0M
72nd
|
$1.2B
79th
|
| Total assets | $3.7B
55th
|
$6.7B
66th
|
$16.9B
83rd
|
| Shareholders' equity | $12.8M
3rd
|
$2.8B
62nd
|
$7.5B
83rd
|
| Employees | 16,600
72nd
|
8,600
59th
|
51,500
86th
|
Price performance
9 measures| Measure | MTD | ILMN | DGX |
|---|---|---|---|
| 1 day | −1.1% | −2.0% | −1.7% |
| 1 week | +4.6% | −5.6% | +1.7% |
| 1 month | +14.9% | +7.1% | −5.0% |
| 3 months | +27.2% | +42.2% | +13.2% |
| 6 months | +20.9% | +95.2% | +20.5% |
| Year to date | +14.8% | +95.4% | +35.8% |
| 1 year | +24.3% | +182.3% | +25.4% |
| 3 years, cumulative | +46.4% | +95.9% | +99.3% |
| 5 years, cumulative | +17.0% | −34.1% | +79.3% |
Technicals
4 measures| Measure | MTD | ILMN | DGX |
|---|---|---|---|
| RSI 14 | 71.0 | 53.1 | 51.1 |
| From 52-week high | −2.4% | −15.1% | −5.5% |
| From 52-week low | +58.4% | +180.8% | +37.9% |
| Beta | 1.19 | 1.42 | 0.54 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17